Acute Leukaemia Flashcards

1
Q

What is acute leukaemia characterised by?

A

o Rapid onset
o Early death if untreated (weeks or months)
o Immature cells (blasts)
o Bone marrow failure
anaemia (pallor, fatigue, SoB),
neutropoenia (infections),
thrombocytopaenia (bleeding)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Where do the mutations occur in leukaemia?

A

• The leukaemias arise due to the presence of mutations at various point in the B and T cell lineages

• CML occurs at the pluripotent haemopoietic stem cell level because during the chronic phase it is characterised by overproduction of myelocytes, however, when it turns acute, it can then have a lymphoblastic crisis
o I.E. CML  ALL blast crisis

• AML can also occur at a pluripotent haemopoietic stem cell level meaning that it presents as a myeloid leukaemia but then relapse later on as an acute lymphoid leukaemia
o I.E. AML  ALL many years later in relapse

• Other AMLs can occur at a multipotent stem cell level or a granulocyte-monocyte precursor level

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When do AML present

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What chromosomal abnormalities can you get in AML?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe chromosomal translocation?

A

oInversion or translocations (alters the DNA sequence)

  • Creates new fusion genes ALL and AML
    • Acute Myeloid Leukaemia / AML; t (8; 21) -> RUNX1+RUNX1T1 15% of AML
    o Partial block – some mature cells remain
    • Core Binding Factor – AML / CBF-AML; Inv (16), t (16; 16) -> fusion gene 12% of AML
    o Partial block – some mature ‘eosinophil-type’ cells remain
    • Acute Promyelocytic Leukaemia / APML; t (15; 17) -> PML-RARA APML
  • Abnormally regulates genes ALL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe chromosomal duplication

A
  • Common in AML
  • Trisomy 8 and Trisomy 21 (gives a predisposition to AML → as seen in TAM in Down’s syndrome)
  • There is a possible dosage effect associated with these trisomy’s (having 3 copies of a proto-oncogene rather than 2 may be the underlying trigger of the leukaemia)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe chromosomal loss and deletion.

A
  • Common in AML
  • MOST COMMON = del (5q) or del (7q)
  • Leukaemogenesis from…
    • Due to loss of tumour suppressor gene
    • One copy of an allele may be insufficient for normal haemopoiesis
    • Possible loss of DNA repair systems
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What molecular abnormalities can occur in chromosomes?

A
  • Point mutations (associated with AML) → prognostic implications
  • Loss of function of tumour suppressor genes
  • Partial duplication
  • Cryptic deletion (fusion gene forms deletion of tiny bit of DNA and remaining ends joining up)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does maturation differ in AML?

A

Excess of myeloblasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
A

AML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why do people get AML?

A
  • Familial or constitutional predisposition (e.g. Down syndrome)
  • Irradiation
  • Anticancer drugs
  • Cigarette smoking
  • Unknown
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does laeukamogenesis occur in AML?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the 2 types of abnormalities in AML?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does differentiation occur?

A
  • Transcription factors are very important in differentiation as they:
    • Bind to DNA
    • Alter structure to favour transcription
    • Regulate gene expression
      • Thus, disruption of transcription factor function can result in failure of differentiation – 2 examples:
        • (1) t(8; 21)
        • (2) inv(16)
      • Core Binding Factors are
        • Dimeric transcription factor
        • Master controllers of haemopoiesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What happens in core binding factor leukaemia?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What happens in core binding factor leukaemia?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
A

t(8;21) - some maturation

18
Q

Describe the inversion blocking differentiation in AML?

A
19
Q

Describe acute promyelocytic leukaemia with t(15;17)

A
  • Pathophysiology = t (15; 17) → PML-RARA fusion gene
    • Causes haemorrhage (e.g. sudden onset bruising or bleeding) – exhibits DIC and hyperactive fibrinolysis
    • Slightly later block in maturation than in classic AML
    • Most patient can be cured as molecular mechanism understood
    • Characterised by an excess of abnormal promyelocytes (Auer rods)
20
Q

Where does the maturation defect occur in t(15;17)

A
21
Q

What are the 2 morphological forms of acute promyelocytic leukaemia?

A
  • There are two morphological variants but the same phenotypic disease and molecular patterns
    • Variant form = granules still present at resolution below that of a light microscope so can’t see all of them
    • Variant form is characterised by bilobed nuclei
22
Q

What are the 2 mutations in acute promyelocytic leukaemia?

A
23
Q

What are the 2 mutations in CBF leukaemia?

A
24
Q

How do you know if it is AML or ALL?

A
  • Cytological features
  • Cytochemistry
  • Immunophenotyping
25
Q

What difference would you find on investigations?

A
26
Q

What are the clinical features of AML?

A
  • Bone marrow failure (anaemia, neutropoenia/infection, thrombocytopaenia)
    • RBCs → SoB, pallor, anaemia
    • WCC → infections
    • Platelets → bleeding and bruising (APML → haemorrhage as fibrinolysis upregulated)
    • Local infiltration:
      • Splenomegaly
      • Hepatomegaly
      • Gum infiltration (monocytic leukaemia; i.e. APML)
      • Skin, CNS or other sites (monocytic leukaemia; i.e. APML) – i.e. cranial nerve palsies
      • Lymphadenopathy (occasionally – more in lymphomas)
    • Hyperviscosity if WBC is very high → retinal haemorrhages or retinal exudates
27
Q

What can be the complications of bone marrow failure infection in AML?

A
  • May be severe and life threatening
  • septic shcok
  • renal failure
    • DIC
28
Q

How dose diagnose AML?

A
  • Blood count, blood film and BM aspirate → diagnostic with presence of circulating blasts ± cytochemistry*
    • Auer rods = AML; presence of granules = AML
      • If neither… use immunophenotyping to determine AML vs ALL
      • Aleukaemic leukaemia (i.e. no peripheral blood leukaemic cells → need to do a BM aspirate)
    • Cytogenetic studies (all newly diagnosed patients)
  • Immunophenotyping (immunohistochemistry, immunocytochemistry → determine AML from ALL)
  • Molecular studies and FISH (some patients) → enable sub-classification of the acute myeloid leukaemia and adds prognostic value and aids treatment decisions (certain cytogenetic findings aid prognosis)
29
Q

How do we treated AML?

A
  • (1) Supportive
    • Red cells
    • Platelets
    • FFP/cryoprecipitate if DIC
    • Antibiotics
    • Long line
    • Allopurinol, fluid and electrolyte balance
  • (2) Chemotherapy:
  • (3) Targeted molecular therapy:
  • (4) Transplantation
30
Q

What does chemotherapy entail?

A
  • Damage DNA of leukaemic cells → target continuously dividing cells that lack cell cycle checkpoint control
  • Combination chemotherapy:
    • Different mechanisms of action that work in synergy
    • Important to ensure non-overlapping toxicity
31
Q

How long do you give chemotherapy for?

A
  • Treatment:
    • Cell-cycle specific drugs
    • 4-5 courses (remission induction x2; consolidation x2-3)
    • After 6 months stop, but consider transplantation if poor prognosis
32
Q

What does targeted molecular therapy entail?

A
  • APML = All-trans-retinoic acid (ATRA) and A2O3
  • Ph +ve (CML, but also rare AML cases) = tyrosine kinase inhibitors
  • Biologics = anti-CD33 antibody linked to cytotoxic antibody (e.g. gemtuzumab)
  • Drugs targeting products of other mutated genes
  • Antibody tx e.g. gentuzumab, ozogamicin, a cytotoxic antibiotic linked to an anti-CD33 antibody
33
Q
  • Why have the results of AML treatment improved?
A
  • Better supportive care
  • Identification of poor prognosis groups
  • Specific treatment for APML
34
Q

What are determinants of prognosis in AML?

A
  • Patient characteristics
  • Morphology
  • Immunophenotyping
  • Cytogenetics
  • Genetics
  • Response to treatment
35
Q

When does ALL present?

A
  • Peak incidence in childhood (MOST COMMON childhood malignancy  85% of children are cured)
  • Prognosis is worse with increasing age
36
Q

What are the clinical features of ALL?

A
  • Signs and symptoms:
    • Bone marrow failure (anaemia, thrombocytopenia, neutropoenia)
    • Local infiltration
      • Lymphadenopathy (± thymic enlargement)
      • Splenomegaly
      • Hepatomegaly
      • Testes, CNS (these are ‘sanctuary sites’ as chemotherapy cannot reach them easily)
      • Bone (causing pain)
37
Q

What are the pathological features of ALL?

A
  • Peripheral blood (blood film) → anaemia, neutropoenia, thrombocytopaenia, lymphoblasts
  • Bone marrow → lymphoblastic infiltration (B- or T-lineage – different genetic defects predispose to each)
    • B-Lineage ALL
      • Starts in the Bone marrow
      • T-Lineage ALL
        • Start in the Thymus (which may be enlarged)
38
Q

What are the genetic features of ALL?

A
  • Prognosis is very dependent on cytogenetic/genetic subgroups (particularly for B-lineage)
  • GOOD Prognosis:
    • Hyperdiploidy t(12;21) t(1;19) TK inhibitors (Ph +ve; t(9; 22)
    • POOR Prognosis:
      • t(4;11) Hypodiploidy (before TKI, Ph +ve)
39
Q

What are the leukaemogenic mechanisms in ALL?

A
  • Proto-oncogene dysregulation → chromosomal translocation:
    • Fusion genes
    • Wrong gene promoter
    • Dysregulation by proximity to TCR or immunoglobulin heavy chain loci
    • Unknown – hyperdiploidy
40
Q

How do we diagnose ALL?

A
  • Clinical suspicion
  • Blood count and film
  • Bone marrow aspirate
  • Immunophenotyping (diagnostic) – this is very important because…
    • AML and ALL are treated very differently
    • Moreover, B-lineage (85%) and T-lineage (15%) are treated very differently
    • Cytogenetic/molecular genetic analysis – this is very important because…
      • Philadelphia chromosome +ve needs imatinib
      • Treatment tailored to prognosis (intensify treatment if bad prognosis)
    • Blood group, LFTs, creatinine, electrolytes, calcium, phosphate, uric acid, coagulation screen
41
Q

How do we treat ALL?

A
  • (1) Supportive:
    • Blood products
    • Antibiotics (broad-spectrum for fever; prophylaxis for PCP infection)
    • General medical care
      • Central venous catheter Hyperuricaemia management
      • Hyperkalaemia management Sometimes haemodialysis
  • (2) Chemotherapy (systemic + CNS-intrathecal-specific):
    • Systemic = 2-3 years of therapy (induction and consolidation):
      • Boys treated for longer because testes are a site of accumulation of lymphoblasts
      • CNS-specific (done in all patients even if initial LP is negative):
        • Can also be done by giving high-dose chemotherapy so that it penetrates the BBB
  • (3) Molecular treatment:
    • TKI for Ph +ve cases
    • Rituximab (monoclonal antibodies against CD20)
  • (4) Transplantation